Prime Medicine, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Prime Medicine, Inc. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $138.38M, a 263.38% increase year-over-year.
- Prime Medicine, Inc. stock issued during period, value, new issues for the quarter ending 2024-09-30 was $38.08M.
- Prime Medicine, Inc. stock issued during period, value, new issues for the quarter ending 2024-03-31 was $132.06M.
- Prime Medicine, Inc. stock issued during period, value, new issues for fiscal 2022 was $180.19M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-09-30 | $138.38M 10-Q · filed 2025-11-07 | |
| 2024-09-30 | $38.08M 10-Q · filed 2025-11-07 | |
| 2024-03-31 | $132.06M 10-Q · filed 2025-11-07 | |
| 2022-12-31 | $180.19M 10-K · filed 2024-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |